Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

How can I find out more?

Further information about oral semaglutide can be found in the current summary of product characteristics. If you would like to discuss any aspect of the study please contact the ASCEND PLUS team.  

 

  • ASCEND PLUS (A Study of Cardiovascular Events iN Diabetes PLUS) is a randomised double-blind placebo-controlled trial sponsored by the University of Oxford.
  • ASCEND PLUS is registered with clinicaltrials.gov (NCT05441267) and ISRCTN (ISRCTN76193287).
  • The UTN universal trial number for ASCEND PLUS is U1111-1284-0262.
  • Protocol [PDF]